(PHIA) Koninklijke Philips - Overview
Sector: HealthcareIndustry: Medical Devices | Exchange AS (Netherlands) | Currency EUR | Market Cap: 25.825m | Total Return 2.3% in 12m
Stock: Medical Imaging, Patient Monitoring, Health Informatics, Personal Care
Total Rating 53
Risk 78
Buy Signal -0.53
| Risk 5d forecast | |
|---|---|
| Volatility | 33.3% |
| Relative Tail Risk | -23.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.21 |
| Alpha | -3.15 |
| Character TTM | |
|---|---|
| Beta | 0.350 |
| Beta Downside | 0.327 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.92% |
| CAGR/Max DD | 0.55 |
EPS (Earnings per Share)
Revenue
Description: PHIA Koninklijke Philips March 05, 2026
Koninklijke Philips N.V. (PHIA) is a health technology company operating globally, with significant presence in North America and Greater China.
The companys business model focuses on three core segments: Diagnosis & Treatment, Connected Care, and Personal Health. The Diagnosis & Treatment segment includes diagnostic imaging (ultrasound, MRI, CT, X-ray) and image-guided therapy systems and devices. This sector is characterized by high research and development costs due to technological advancements and regulatory requirements.
Connected Care offers monitoring, enterprise informatics, and sleep and respiratory care solutions, addressing the growing demand for remote patient management. Personal Health encompasses consumer-oriented health products.
Philips historical evolution from Koninklijke Philips Electronics N.V. to its current health technology focus reflects a strategic shift towards the healthcare sector, a resilient industry with consistent demand.
Further analysis of PHIAs financial performance and competitive landscape can be found on ValueRay.
Headlines to watch out for
- Healthcare systems capital expenditure drives diagnostic and treatment equipment sales
- Connected Care segment revenue impacted by hospital IT budgets
- Regulatory scrutiny on medical device safety increases compliance costs
- Personal Health product demand sensitive to consumer discretionary spending
- Supply chain disruptions affect production and delivery of medical devices
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 895.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.48 > 1.0 |
| NWC/Revenue: 13.59% < 20% (prev 10.42%; Δ 3.17% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.17b > Net Income 895.0m |
| Net Debt (5.29b) to EBITDA (2.71b): 1.96 < 3 |
| Current Ratio: 1.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (965.9m) vs 12m ago 3.49% < -2% |
| Gross Margin: 45.18% > 18% (prev 0.43%; Δ 4.48k% > 0.5%) |
| Asset Turnover: 63.78% > 50% (prev 62.19%; Δ 1.59% > 0%) |
| Interest Coverage Ratio: 4.82 > 6 (EBITDA TTM 2.71b / Interest Expense TTM 328.0m) |
Altman Z'' 1.67
| A: 0.09 (Total Current Assets 9.93b - Total Current Liabilities 7.51b) / Total Assets 26.94b |
| B: 0.13 (Retained Earnings 3.58b / Total Assets 26.94b) |
| C: 0.06 (EBIT TTM 1.58b / Avg Total Assets 27.96b) |
| D: 0.25 (Book Value of Equity 4.04b / Total Liabilities 15.96b) |
| Altman-Z'' Score: 1.67 = BB |
Beneish M -3.20
| DSRI: 0.88 (Receivables 3.59b/4.12b, Revenue 17.83b/18.02b) |
| GMI: 0.95 (GM 45.18% / 43.13%) |
| AQI: 0.96 (AQ_t 0.55 / AQ_t-1 0.57) |
| SGI: 0.99 (Revenue 17.83b / 18.02b) |
| TATA: -0.01 (NI 895.0m - CFO 1.17b) / TA 26.94b) |
| Beneish M-Score: -3.20 (Cap -4..+1) = AA |
What is the price of PHIA shares?
As of March 29, 2026, the stock is trading at EUR 23.48 with a total of 1,065,876 shares traded.
Over the past week, the price has changed by +2.85%, over one month by -13.29%, over three months by +1.51% and over the past year by +2.26%.
Over the past week, the price has changed by +2.85%, over one month by -13.29%, over three months by +1.51% and over the past year by +2.26%.
Is PHIA a buy, sell or hold?
Koninklijke Philips has no consensus analysts rating.
What are the forecasts/targets for the PHIA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.5 | 21.3% |
| Analysts Target Price | - | - |
PHIA Fundamental Data Overview March 28, 2026
Market Cap USD = 25.83b (22.34b EUR * 1.1562 EUR.USD)
P/E Trailing = 25.2473
P/E Forward = 14.4092
P/S = 1.2525
P/B = 1.9821
P/EG = 0.3634
Revenue TTM = 17.83b EUR
EBIT TTM = 1.58b EUR
EBITDA TTM = 2.71b EUR
Long Term Debt = 6.05b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.15b EUR (from shortTermDebt, last quarter)
Debt = 8.09b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.29b EUR (from netDebt column, last quarter)
Enterprise Value = 27.63b EUR (22.34b + Debt 8.09b - CCE 2.79b)
Interest Coverage Ratio = 4.82 (Ebit TTM 1.58b / Interest Expense TTM 328.0m)
EV/FCF = 39.41x (Enterprise Value 27.63b / FCF TTM 701.0m)
FCF Yield = 2.54% (FCF TTM 701.0m / Enterprise Value 27.63b)
FCF Margin = 3.93% (FCF TTM 701.0m / Revenue TTM 17.83b)
Net Margin = 5.02% (Net Income TTM 895.0m / Revenue TTM 17.83b)
Gross Margin = 45.18% ((Revenue TTM 17.83b - Cost of Revenue TTM 9.78b) / Revenue TTM)
Gross Margin QoQ = 44.89% (prev 44.40%)
Tobins Q-Ratio = 1.03 (Enterprise Value 27.63b / Total Assets 26.94b)
Interest Expense / Debt = 1.35% (Interest Expense 109.0m / Debt 8.09b)
Taxrate = 15.67% (73.0m / 466.0m)
NOPAT = 1.33b (EBIT 1.58b * (1 - 15.67%))
Current Ratio = 1.32 (Total Current Assets 9.93b / Total Current Liabilities 7.51b)
Debt / Equity = 0.74 (Debt 8.09b / totalStockholderEquity, last quarter 10.96b)
Debt / EBITDA = 1.96 (Net Debt 5.29b / EBITDA 2.71b)
Debt / FCF = 7.55 (Net Debt 5.29b / FCF TTM 701.0m)
Total Stockholder Equity = 10.90b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.20% (Net Income 895.0m / Total Assets 26.94b)
RoE = 8.21% (Net Income TTM 895.0m / Total Stockholder Equity 10.90b)
RoCE = 9.33% (EBIT 1.58b / Capital Employed (Equity 10.90b + L.T.Debt 6.05b))
RoIC = 7.13% (NOPAT 1.33b / Invested Capital 18.70b)
WACC = 5.60% (E(22.34b)/V(30.42b) * Re(7.21%) + D(8.09b)/V(30.42b) * Rd(1.35%) * (1-Tc(0.16)))
Discount Rate = 7.21% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 2.06%
[DCF] Terminal Value 80.82% ; FCFF base≈778.2m ; Y1≈510.9m ; Y5≈233.6m
[DCF] Fair Price = 2.23 (EV 7.42b - Net Debt 5.29b = Equity 2.13b / Shares 951.3m; r=6.0% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 41.97 | EPS CAGR: 13.38% | SUE: 0.35 | # QB: 0
Revenue Correlation: 22.11 | Revenue CAGR: 7.27% | SUE: 0.51 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.37 | Chg7d=-0.000 | Chg30d=-0.000 | Revisions Net=-1 | Analysts=2
EPS current Year (2026-12-31): EPS=1.52 | Chg7d=+0.002 | Chg30d=-0.002 | Revisions Net=-1 | Growth EPS=-2.5% | Growth Revenue=+0.7%
EPS next Year (2027-12-31): EPS=1.71 | Chg7d=+0.003 | Chg30d=-0.000 | Revisions Net=+0 | Growth EPS=+12.5% | Growth Revenue=+4.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.0% (Discount Rate 7.9% - Earnings Yield 4.0%)
[Growth] Growth Spread = -4.3% (Analyst -0.4% - Implied 4.0%)
P/E Trailing = 25.2473
P/E Forward = 14.4092
P/S = 1.2525
P/B = 1.9821
P/EG = 0.3634
Revenue TTM = 17.83b EUR
EBIT TTM = 1.58b EUR
EBITDA TTM = 2.71b EUR
Long Term Debt = 6.05b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.15b EUR (from shortTermDebt, last quarter)
Debt = 8.09b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.29b EUR (from netDebt column, last quarter)
Enterprise Value = 27.63b EUR (22.34b + Debt 8.09b - CCE 2.79b)
Interest Coverage Ratio = 4.82 (Ebit TTM 1.58b / Interest Expense TTM 328.0m)
EV/FCF = 39.41x (Enterprise Value 27.63b / FCF TTM 701.0m)
FCF Yield = 2.54% (FCF TTM 701.0m / Enterprise Value 27.63b)
FCF Margin = 3.93% (FCF TTM 701.0m / Revenue TTM 17.83b)
Net Margin = 5.02% (Net Income TTM 895.0m / Revenue TTM 17.83b)
Gross Margin = 45.18% ((Revenue TTM 17.83b - Cost of Revenue TTM 9.78b) / Revenue TTM)
Gross Margin QoQ = 44.89% (prev 44.40%)
Tobins Q-Ratio = 1.03 (Enterprise Value 27.63b / Total Assets 26.94b)
Interest Expense / Debt = 1.35% (Interest Expense 109.0m / Debt 8.09b)
Taxrate = 15.67% (73.0m / 466.0m)
NOPAT = 1.33b (EBIT 1.58b * (1 - 15.67%))
Current Ratio = 1.32 (Total Current Assets 9.93b / Total Current Liabilities 7.51b)
Debt / Equity = 0.74 (Debt 8.09b / totalStockholderEquity, last quarter 10.96b)
Debt / EBITDA = 1.96 (Net Debt 5.29b / EBITDA 2.71b)
Debt / FCF = 7.55 (Net Debt 5.29b / FCF TTM 701.0m)
Total Stockholder Equity = 10.90b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.20% (Net Income 895.0m / Total Assets 26.94b)
RoE = 8.21% (Net Income TTM 895.0m / Total Stockholder Equity 10.90b)
RoCE = 9.33% (EBIT 1.58b / Capital Employed (Equity 10.90b + L.T.Debt 6.05b))
RoIC = 7.13% (NOPAT 1.33b / Invested Capital 18.70b)
WACC = 5.60% (E(22.34b)/V(30.42b) * Re(7.21%) + D(8.09b)/V(30.42b) * Rd(1.35%) * (1-Tc(0.16)))
Discount Rate = 7.21% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 2.06%
[DCF] Terminal Value 80.82% ; FCFF base≈778.2m ; Y1≈510.9m ; Y5≈233.6m
[DCF] Fair Price = 2.23 (EV 7.42b - Net Debt 5.29b = Equity 2.13b / Shares 951.3m; r=6.0% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 41.97 | EPS CAGR: 13.38% | SUE: 0.35 | # QB: 0
Revenue Correlation: 22.11 | Revenue CAGR: 7.27% | SUE: 0.51 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.37 | Chg7d=-0.000 | Chg30d=-0.000 | Revisions Net=-1 | Analysts=2
EPS current Year (2026-12-31): EPS=1.52 | Chg7d=+0.002 | Chg30d=-0.002 | Revisions Net=-1 | Growth EPS=-2.5% | Growth Revenue=+0.7%
EPS next Year (2027-12-31): EPS=1.71 | Chg7d=+0.003 | Chg30d=-0.000 | Revisions Net=+0 | Growth EPS=+12.5% | Growth Revenue=+4.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.0% (Discount Rate 7.9% - Earnings Yield 4.0%)
[Growth] Growth Spread = -4.3% (Analyst -0.4% - Implied 4.0%)